tldrdailynews.com logo

Eli Lilly's Oral GLP-1 Therapy Sustains Weight Loss Post-Injection

1 min read
Source: Eli Lilly
TL;DR

Eli Lilly's oral GLP-1 receptor agonist, orforglipron, successfully maintained weight loss in a Phase 3 trial after patients switched from injectable therapies, leading Lilly to submit it for FDA approval as a treatment for obesity.

Topics:businesshealthcare#healthcare#lilly#obesity#orforglipron#phase3#weightloss
Share this article
  1. Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial  Eli Lilly
  2. Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound  CNBC
  3. People Are Already Taking This Unapproved New Weight-Loss Drug  WIRED
  4. Major Weight Loss and Knee-Pain Relief Seen With New Eli Lilly Drug  The New York Times
  5. Lilly's obesity pill largely maintains weight lost on injectable GLP-1s  Fierce Biotech

Want the full story? Read the original reporting

Read on Eli Lilly